- Home
- CCS vs MIRM Comparison
CCS vs MIRM Comparison
Compare CCS & MIRM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CCS
- MIRM
- Stock Information
- Founded
- CCS 2000
- MIRM 2018
- Country
- CCS United States
- MIRM United States
- Employees
- CCS N/A
- MIRM N/A
- Industry
- CCS Homebuilding
- MIRM Biotechnology: Pharmaceutical Preparations
- Sector
- CCS Consumer Discretionary
- MIRM Health Care
- Exchange
- CCS Nasdaq
- MIRM Nasdaq
- Market Cap
- CCS 2.7B
- MIRM 2.2B
- IPO Year
- CCS 2014
- MIRM 2019
- Fundamental
- Price
- CCS $67.46
- MIRM $44.56
- Analyst Decision
- CCS Buy
- MIRM Strong Buy
- Analyst Count
- CCS 4
- MIRM 11
- Target Price
- CCS $104.00
- MIRM $58.55
- AVG Volume (30 Days)
- CCS 397.5K
- MIRM 593.0K
- Earning Date
- CCS 04-23-2025
- MIRM 05-07-2025
- Dividend Yield
- CCS 1.72%
- MIRM N/A
- EPS Growth
- CCS 29.19
- MIRM N/A
- EPS
- CCS 10.40
- MIRM N/A
- Revenue
- CCS $4,398,288,000.00
- MIRM $336,888,000.00
- Revenue This Year
- CCS $12.41
- MIRM $27.25
- Revenue Next Year
- CCS $8.21
- MIRM $21.81
- P/E Ratio
- CCS $6.47
- MIRM N/A
- Revenue Growth
- CCS 19.12
- MIRM 80.76
- 52 Week Low
- CCS $66.71
- MIRM $23.14
- 52 Week High
- CCS $108.42
- MIRM $54.23
- Technical
- Relative Strength Index (RSI)
- CCS 37.98
- MIRM 40.19
- Support Level
- CCS $66.72
- MIRM $42.01
- Resistance Level
- CCS $73.37
- MIRM $46.02
- Average True Range (ATR)
- CCS 2.40
- MIRM 2.12
- MACD
- CCS -0.10
- MIRM -0.54
- Stochastic Oscillator
- CCS 9.20
- MIRM 23.12
About CCS Century Communities Inc.
Century Communities Inc is a construction company that focuses on the residential market. It has five homebuilding segments: West, Mountain, Texas, Southeast, and Century Complete. Its sixth reportable segment is financial services operations, which provides mortgage, title, and insurance services to homebuyers. It has acquired land for homebuilding operations with the primary intent to develop and construct single-family detached or attached homes for sale on the acquired land. The company sells homes through its own sales representatives and independent real estate brokers. It also advertises directly to potential homebuyers through the Internet, newspapers, and trade publications. The company generates the majority revenue from the Mountain segment.
About MIRM Mirum Pharmaceuticals Inc.
Mirum Pharmaceuticals Inc is a biopharmaceutical company focused on the identification, acquisition, development, and commercialization of novel therapies for debilitating rare and orphan diseases. Its product, Livmarli, a novel, orally administered, minimally-absorbed ileal bile acid transporter IBAT) inhibitor (IBATi), is approved for the treatment of cholestatic pruritus in patients with Alagille syndrome (ALGS). It is involved in the development of Maralixibat for the treatment of pediatric patients with progressive familial intrahepatic cholestasis, or PFIC, and Alagille syndrome, or ALGS. The company is also involved in the development of volixibat for the treatment of adult patients with cholestatic liver diseases.